Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Chemokine receptor CCR5 in interferon-treated multiple sclerosis.

Acta neurologica Scandinavica - 1 Jun 2007

Sellebjerg F, Kristiansen T B, Wittenhagen P, Garred P, Eugen-Olsen J, Frederiksen J L, Sørensen T L

Abstract excerpt

OBJECTIVE: To study the relationship between CC chemokine receptor CCR5 expression and disease activity in multiple sclerosis (MS) patients treated with beta-interferon (IFN-beta). METHODS: The CCR5 Delta32 allele and a CCR5 promoter polymorphism associated with cell surface expression of CCR5 we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Central Nervous System
Share to Genetic Testing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-beta

Share to Interferons

Share to Monocytes

Share to Multiple Sclerosis, Relapsing-Remitting

Share to Receptors, CCR5

Source

Identifiers

PMID: 17511851
DOI: 10.1111/j.1600-0404.2007.00826.x

Genes

CCR5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17511851-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Chemokine receptor CCR5 in interferon-treated multiple sclerosis.PMID 17511851Read ↗

CCR5 delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis.Semantic proximity Read ↗

The chemokine receptor CCR5 Δ32 allele in natalizumab-treated multiple sclerosis.Semantic proximity Read ↗

Increase in CCR5 Delta32/Delta32 genotype in multiple sclerosis.Semantic proximity Read ↗

CCR5Delta32 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis.Semantic proximity Read ↗

CCR5Δ32 - A piece of protection in the inflammatory puzzle of multiple sclerosis susceptibility.Semantic proximity Read ↗

Influence of CCR5 delta32 polymorphism on multiple sclerosis susceptibility and disease course.Semantic proximity Read ↗

CCL5 and CCR5 genotypes modify clinical, radiological and pathological features of multiple sclerosis.Semantic proximity Read ↗

Complex immunomodulatory effects of interferon‐β in multiple sclerosis include the upregulation of T helper 1‐associated marker genesSemantic proximity Read ↗

Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonβ therapy in multiple sclerosis.Semantic proximity Read ↗

Association of CCR5 delta32 deletion with early death in multiple sclerosis.Semantic proximity Read ↗

CC chemokine receptor 5 polymorphism in rheumatoid arthritis.Semantic proximity Read ↗

Prediction of response to interferon therapy in multiple sclerosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.